As a Coloradan living with Cystic Fibrosis (CF), I am deeply concerned about the potential decision by the Colorado state board to cap the price of Trikafta. This groundbreaking medication has been hailed as a "miracle" drug for individuals like me, providing hope and transforming lives. However, imposing price restrictions could have severe consequences, including the possibility of the manufacturer no longer selling this life-changing medication in our state.

Trikafta has revolutionized CF treatment by targeting the underlying cause of this progressive genetic disease. It is estimated that around 90% of individuals with CF can benefit from this medication, regardless of their specific genetic mutations. The drug significantly improves lung function, reduces hospitalizations and exacerbations, and enhances overall quality of life.

For me personally, Trikafta has been nothing short of life-altering. Prior to its availability, I would spend weeks in hospitals every year fearing that my condition would deteriorate to the point where I would require a lung transplant. The burden was immense not only on my physical health but also on my mental well-being and independence.

Since starting Trikafta treatment, I have experienced an incredible transformation. I now live a fully independent life without constant fears of hospitalization or declining lung function. Previously requiring daily or even twice-daily treatments just to maintain stability is no longer necessary because this pill provides comprehensive relief.

However, news about potential price caps threatens access to this vital medication for countless individuals in Colorado who rely on it for survival and improved health outcomes. While it is crucial to ensure affordability for all patients who need Trikafta within our state's healthcare system, we must also consider its long-term availability.

Imposing price restrictions may discourage pharmaceutical companies from supplying Trikafta in Colorado, jeopardizing the lives and well-being of CF patients who depend on it. We must find a balanced solution that ensures affordability without compromising access to this life-saving drug.

I urge the Colorado state board to reconsider their decision to cap the price of Trikafta. Let us work together towards a fair and sustainable pricing model that guarantees access for all Coloradans with CF, while also encouraging continued innovation and research in the field of rare disease treatments.

By signing this petition, you are joining me in advocating for the rights of individuals with Cystic Fibrosis in Colorado. Together, let's ensure that Trikafta remains accessible to those who desperately need it, enabling them to lead healthier, more fulfilling lives.

Logan Roberts